ES454779A1 - Procedimiento para la obtencion de hidroxidiheterociclos eterados. - Google Patents

Procedimiento para la obtencion de hidroxidiheterociclos eterados.

Info

Publication number
ES454779A1
ES454779A1 ES454779A ES454779A ES454779A1 ES 454779 A1 ES454779 A1 ES 454779A1 ES 454779 A ES454779 A ES 454779A ES 454779 A ES454779 A ES 454779A ES 454779 A1 ES454779 A1 ES 454779A1
Authority
ES
Spain
Prior art keywords
formula
group
radical
denotes
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES454779A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES454779A1 publication Critical patent/ES454779A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procedimiento para la obtención de hidroxibenzodiheterociclos eterados. Los nuevos compuestos presentan valiosas propiedades farmacológicas, especialmente efectos bloqueadores de los beta-receptores fuertes y de larga duración, lo que se puede demostrar a base de los correspondientes ensayos farmacológicos. Así presentan los nuevos compuestos una inhibición de la taquicardia por isoproterenol en el corazón de la cobaya aislado en un margen de concentración de aproximadamente 0,001my-g/cc hasta unos 1 my-g/cc y una inhibición de la taquicardia y vasodilatación por isoproterenol en el gato narcotizado en un margen de dosificación de unos 0,0003 mg/kg hasta unos 0,3 mg/kg en administración intravenosa.
ES454779A 1976-01-08 1977-01-04 Procedimiento para la obtencion de hidroxidiheterociclos eterados. Expired ES454779A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH16176A CH624395A5 (es) 1976-01-08 1976-01-08

Publications (1)

Publication Number Publication Date
ES454779A1 true ES454779A1 (es) 1978-01-01

Family

ID=4180641

Family Applications (1)

Application Number Title Priority Date Filing Date
ES454779A Expired ES454779A1 (es) 1976-01-08 1977-01-04 Procedimiento para la obtencion de hidroxidiheterociclos eterados.

Country Status (26)

Country Link
US (2) US4140789A (es)
JP (1) JPS5285166A (es)
AR (4) AR214869A1 (es)
AT (1) AT355564B (es)
AU (1) AU507884B2 (es)
BE (1) BE850166A (es)
CA (1) CA1083150A (es)
CH (1) CH624395A5 (es)
CS (1) CS201040B2 (es)
DD (1) DD129444A5 (es)
DE (1) DE2700193A1 (es)
DK (1) DK6177A (es)
ES (1) ES454779A1 (es)
FI (1) FI770036A (es)
FR (1) FR2337718A1 (es)
GB (1) GB1549945A (es)
GR (1) GR73132B (es)
IE (1) IE44246B1 (es)
IL (1) IL51222A (es)
NL (1) NL7700141A (es)
NO (1) NO770061L (es)
NZ (1) NZ182963A (es)
PL (4) PL112441B1 (es)
SE (1) SE7700056L (es)
SU (4) SU648091A3 (es)
ZA (1) ZA7787B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (es) * 1976-01-08 1981-07-31 Ciba Geigy Ag
DE2644833A1 (de) * 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
NZ187066A (en) * 1977-05-03 1981-02-11 Hoffmann La Roche 4-(3-substitutedamino-2-hydroxypropoxy)-benzimidazolidin-2-(ones or thiones)
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
DE2801980A1 (de) * 1978-01-18 1979-07-19 Boehringer Mannheim Gmbh 4-hydroxy-2-benzimidazolin-thion- derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
EP0003758A1 (de) * 1978-02-09 1979-09-05 Ciba-Geigy Ag Verätherte Hydroxy-benzodiheterocyclen und ihre Säureadditionssalze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
FR2455587A1 (fr) 1979-05-04 1980-11-28 Continental Pharma Derives de benzimidazole, leur preparation et utilisation dans le traitement des affections cardiovasculaires et compositions les contenant
DE2922084A1 (de) 1979-05-31 1980-12-11 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4349673A (en) * 1980-12-23 1982-09-14 Merck & Co., Inc. Benzoxazines
US4331679A (en) * 1980-12-23 1982-05-25 Merck Sharp & Dohme (I.A.) Corp. (3-Aralkylamino-2-or-propoxy) heterocyclic compounds
US4442094A (en) * 1980-12-23 1984-04-10 Merck & Co., Inc. (3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US4656168A (en) * 1980-12-23 1987-04-07 Merck & Co., Inc. (3-aralkylamino-2-or-propoxy)heterocyclic compounds in method of effecting bronchodilation
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
IT1212552B (it) * 1982-10-20 1989-11-30 Italo Britannica L Manet Ti H Alcanolaminossi derivati di 3,4-diidro-2h-1.4-benzotiazin-3-one, loro procedimento di produzione e loro utilizzazione farmaceutica
GB8419797D0 (en) * 1984-08-03 1984-09-05 Beecham Group Plc Compounds
DE3800096A1 (de) * 1988-01-05 1989-07-13 Bayer Ag Verwendung von benzimidazolderivaten als leistungsfoerderer
FR2653430B1 (fr) * 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
US6075040A (en) 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
US5972958A (en) * 1997-02-18 1999-10-26 American Home Products Corporation 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
US5990144A (en) * 1997-02-18 1999-11-23 American Home Products Corporation 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
DE59804641D1 (de) * 1997-09-24 2002-08-08 Infineon Technologies Ag o-Nitro(thio)phenolderivate und deren Herstellung
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
AU1580001A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
FR2805159B1 (fr) 2000-02-23 2005-06-10 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n-(2-hydroxybenzene)-carbamate ou un n-(2-hydroxybenzene)-uree a titre de coupleur, et procedes de teinture
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
ES2262817T3 (es) 2001-08-14 2006-12-01 Eli Lilly And Company Agonistas beta-3 oxindol 3-sustituidos.
ES2272749T3 (es) 2001-08-14 2007-05-01 Eli Lilly And Company Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
EP1448561B1 (en) 2001-11-20 2008-02-20 Eli Lilly And Company Beta 3 adrenergic agonists
WO2003044016A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE β3 AGONISTS
JP2005520805A (ja) * 2002-01-11 2005-07-14 イーライ・リリー・アンド・カンパニー ２−オキソ−ベンズイミダゾリル置換型エタノールアミン誘導体およびβ３アゴニストとしてのその使用
NZ538745A (en) 2002-08-29 2007-06-29 Nissan Chemical Ind Ltd Process for producing aminobenzopyran compound
JP2007523873A (ja) * 2003-07-15 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化合物
CN101547922B (zh) * 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA726737A (en) * 1966-01-25 C. Scarborough Homer 4-substituted quinolines and quinazolines
US3686176A (en) * 1970-03-09 1972-08-22 Frosst & Co Charles E 1-morpholino phenoxy-3-alkylamino-2-propanols
US3763153A (en) * 1972-02-22 1973-10-02 Squibb & Sons Inc Benzothiazines
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
CH624395A5 (es) * 1976-01-08 1981-07-31 Ciba Geigy Ag

Also Published As

Publication number Publication date
DE2700193A1 (de) 1977-07-14
ATA4677A (de) 1979-08-15
ZA7787B (en) 1977-11-30
JPS5285166A (en) 1977-07-15
PL112442B1 (en) 1980-10-31
AR214746A1 (es) 1979-07-31
IE44246L (en) 1977-07-08
BE850166A (fr) 1977-07-07
PL112441B1 (en) 1980-10-31
FR2337718A1 (fr) 1977-08-05
AT355564B (de) 1980-03-10
IE44246B1 (en) 1981-09-23
AR217258A1 (es) 1980-03-14
IL51222A (en) 1980-12-31
FR2337718B1 (es) 1980-11-07
IL51222A0 (en) 1977-03-31
AR215643A1 (es) 1979-10-31
NZ182963A (en) 1978-07-28
US4310527A (en) 1982-01-12
SE7700056L (sv) 1977-07-09
SU645568A3 (ru) 1979-01-30
PL112491B1 (en) 1980-10-31
AU2110577A (en) 1978-07-13
GB1549945A (en) 1979-08-08
GR73132B (es) 1984-02-07
SU648091A3 (ru) 1979-02-15
AU507884B2 (en) 1980-02-28
CS201040B2 (en) 1980-10-31
PL110654B1 (en) 1980-07-31
CH624395A5 (es) 1981-07-31
NL7700141A (nl) 1977-07-12
PL195154A1 (pl) 1979-05-07
DK6177A (da) 1977-07-09
DD129444A5 (de) 1978-01-18
NO770061L (no) 1977-07-11
FI770036A (es) 1977-07-09
AR214869A1 (es) 1979-08-15
US4140789A (en) 1979-02-20
SU648092A3 (ru) 1979-02-15
CA1083150A (en) 1980-08-05
SU651695A3 (ru) 1979-03-05

Similar Documents

Publication Publication Date Title
ES454779A1 (es) Procedimiento para la obtencion de hidroxidiheterociclos eterados.
ES486349A1 (es) Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas
DE3271269D1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
ES473816A1 (es) Procedimiento para preparar derivados de piperazina.
NO883994D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidinylaminer.
ATE13765T1 (de) 2-(1,4-benzodioxan-2-ylalkyl)-imidazole, deren herstellung und sie enthaltende pharmazeutische mittel.
ES481551A1 (es) Procedimiento de preparacion de nuevos compuestos bis (ari- loxicarboxilicos).
ES449939A1 (es) Procedimiento para preparar sulfuro de difenilo sustituido.
EP0150015A3 (en) Norbornane and norbornene carboxylic acid amides, process for their preparation and their use as medicines
SE7704829L (sv) Indazolyl-(4)-oxi-propanolaminer
ES472435A1 (es) Procedimiento para la preparacion de derivados de 4-hidroxi-2-bancimidazolinona
AR247483A1 (es) Nuevas metafenilendiaminas trialcoxi-sustituidas, procedimiento de preparacion, composiciones tintoreas para el tenido por oxidacion de fibras queratinicas y en particular de los cabellos humanos
DZ1726A1 (fr) Médicament contenant des composés imidazol-1-yliques.
ES468170A1 (es) Un procedimiento para la preparacion de un nuevo derivado demorfina
ES476449A1 (es) Procedimiento de preparacion de derivados de piridazinona.
NO154391C (no) E 2-amino-naftalen-derivater.
GB2129425B (en) 5-halovinyl-2'-deoxyuridine derivatives
ES474367A1 (es) Procedimiento de preparacion de nuevos derivados del benzo- (d)tiazol.
FR2450835A2 (fr) Derives de la tetrahydroalstonine et leur application en therapeutique
FR2410640A1 (fr) Derives de phenoxyalcanolamines, leur preparation et leurs utilisations therapeutiques
ES8608492A1 (es) Procedimiento para la obtencion de derivados de 3-(ureidociclohexilamino) propan-1, 2-diol
NO164170C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-benzhydryl-4-cinnamyl-piperazinderivater.
ES2002113A6 (es) Procedimiento para la preparacion de derivados de 1-alquil-ergolinil-tiourea
ES8303405A1 (es) Procedimiento de preparacion de derivados de quinidina.
ES474746A1 (es) Ÿun procedimiento de preparacion de derivados de la eburna- meninaŸ